--- title: "P/E Ratio Insights for Regeneron Pharmaceuticals" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/277839030.md" description: "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock is currently priced at $780.00, reflecting a 0.95% drop. Over the past month, the stock has increased by 1.61% and by 12.75% over the past year. The company's P/E ratio stands at 18.48, significantly lower than the Biotechnology industry average of 76.09, suggesting potential undervaluation or lower growth expectations. Investors are advised to consider the P/E ratio alongside other financial metrics and qualitative factors for informed decision-making." datetime: "2026-03-04T22:00:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277839030.md) - [en](https://longbridge.com/en/news/277839030.md) - [zh-HK](https://longbridge.com/zh-HK/news/277839030.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277839030.md) | [English](https://longbridge.com/en/news/277839030.md) # P/E Ratio Insights for Regeneron Pharmaceuticals In the current market session, **Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)** stock price is at $780.00, after a **0.95%** drop. However, over the past month, the company's stock spiked by **1.61%**, and in the past year, by **12.75%**. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. ![Past Year Chart](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg) ### Comparing Regeneron Pharmaceuticals P/E Against Its Peers The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. Compared to the aggregate P/E ratio of the **76.09** in the Biotechnology industry, Regeneron Pharmaceuticals Inc. has a lower P/E ratio of **18.48**. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. ![Guage](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772661628_1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg) In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. ### 相關股票 - [Regeneron Pharma (REGN.US)](https://longbridge.com/zh-HK/quote/REGN.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) ## 相關資訊與研究 - [Regeneron Gets FDA OK for Extended Eylea HD Dosing](https://longbridge.com/zh-HK/news/281556416.md) - [Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients](https://longbridge.com/zh-HK/news/278381000.md) - [09:00 ETDelonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104](https://longbridge.com/zh-HK/news/281025352.md) - [Teva Pharmaceutical Gets US FDA Approval for Prolia Biosimilar; Xoliar Biosimiliar Applications Accepted in US, Europe](https://longbridge.com/zh-HK/news/281026919.md) - [Regeneron Shares Fall After Morgan Stanley Downgrade](https://longbridge.com/zh-HK/news/268484878.md)